Due to the effects of TGF-β on the growth and survival of LSC (Watabe and Miyazono, 2009[53]), CD34+ CML cells were treated with both BMP2/4 and TGF-β1 and their inhibitory effects were evaluated within 48 hours after treatment. The gene discussed is BMP2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.